Contract facts
FederalNo full NAICS 541714 intel page yet. Browse NAICS intelligence
NOVEL NANOTHERAPEUTIC APPROACHES PENETRATING THE OUTER LAYERS OF THE BACTERIUM AND TARGETING OUTER MEMBRANE PROTEINS FOR THE TREATMENT OF PNEUMONIC PLAGUE FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS is a federal award for Army Med Res Acq Activity held by Eitr Biologics, Inc. Estimated value $750K ($750K obligated). Current period of performance ends Aug 31, 2024. Place of performance: SAN DIEGO CA. Related solicitation HT942523R0061.
NOVEL NANOTHERAPEUTIC APPROACHES PENETRATING THE OUTER LAYERS OF THE BACTERIUM AND TARGETING OUTER MEMBRANE PROTEINS FOR THE TREATMENT OF PNEUMONIC PLAGUE FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS
Recompete timing
PublicCurrent PoP ended Aug 31, 2024 (720 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordEitr Biologics, Inc — $37.9M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942523F0306?
HT942523F0306 (NOVEL nanotherapeutic approaches penetrating) is a Army Med Res Acq Activity award with a potential value of $750K, currently held by Eitr Biologics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT9425-23-F-0306?
HT9425-23-F-0306 is the dashed form of PIID HT942523F0306 (NOVEL nanotherapeutic approaches penetrating), held by Eitr Biologics, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT942523F0306?
Army Med Res Acq Activity awarded HT942523F0306 to Eitr Biologics, Inc (potential $750K).
Who is the incumbent on HT942523F0306?
Eitr Biologics, Inc is the incumbent with $37.9M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2024.
When does Eitr Biologics, Inc’s HT942523F0306 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.